Analysis updated on Nov. 4, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Our AI scores Labcorp Holdings Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Labcorp Holdings Inc. is a large-cap company with a market capitalization of $28.74B. It ranks number 2 by market capitalization among the 26 Services-Medical Laboratories issuers in our coverage with a current forecast.
For LH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 21.0%, measured on 358 forecast dates between 2022-08-17 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 1.0%, measured on 400 forecast dates between 2022-08-17 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LH included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
| Metric | LH | Rank |
|---|---|---|
| Market Cap | $28.74B | 2/26 |
| P/E Ratio | 29.03x | 4/6 |
| P/B Ratio | 3.25x | 10/21 |
| Dividend Yield | 0.83% | – |
| EPS | $12.19 | – |
| Book Value/Share | $108.96 | – |
| Revenue/Share | $179.74 | – |
| FCF/Share | $15.85 | – |
| Metric | LH | Rank |
|---|---|---|
| ROE | 11.3% | 3/14 |
| ROA | 5.3% | 4/18 |
| ROIC | 9.3% | 3/21 |
| Gross Margin | 29.0% | 7/15 |
| Operating Margin | 10.3% | 5/21 |
| Net Margin | 6.9% | 4/16 |
| EBT Margin | 8.4% | 5/21 |
| Tax Rate | 17.9% | – |
| Metric | LH | Rank |
|---|---|---|
| Current Ratio | 1.41x | 20/23 |
| Quick Ratio | 1.22x | 10/10 |
| D/E Ratio | 1.14x | 8/21 |
| Financial Leverage | 2.14x | 8/21 |
| Interest Coverage | 6.8x | 1/20 |
| Working Capital | $1.15B | 2/23 |
| Metric | LH | Rank |
|---|---|---|
| Operating Cash Flow | $1.81B | 2/24 |
| Free Cash Flow | $1.29B | 2/17 |
| Capital Spending | -$528M | 16/17 |
| OCF Growth YoY | 0.6% | 7/8 |
| FCF Growth YoY | -6.8% | 3/5 |
| FCF/Sales | 8.8% | 5/16 |
| CapEx/Sales | 3.6% | 10/16 |
| Metric | LH | Rank |
|---|---|---|
| Asset Turnover | 0.77x | 7/18 |
| Receivables Turnover | 6.0x | 13/19 |
| Inventory Turnover | 19.3x | 3/7 |
| Fixed Assets Turnover | 4.6x | 8/17 |
| Days Sales Outstanding | 60 days | 7/19 |
| Days Inventory | 19 days | 5/7 |
| Payables Period | 26 days | 11/13 |
| Cash Conversion Cycle | 53 days | 5/6 |
| Metric | LH | Rank |
|---|---|---|
| Total Revenue | $14.59B | 1/19 |
| Operating Income | $1.50B | 2/23 |
| Net Income | $1.00B | 2/18 |
| SG&A Expense | $2.28B | 1/18 |
| Cost of Goods Sold | $10.37B | 1/14 |
| Metric | LH | Rank |
|---|---|---|
| Dividends Per Share | $2.92 | – |
| Payout Ratio | 23.9% | – |
| Shares Outstanding | 81M | – |
| Net Income Growth | 17.4% | 3/5 |
| EPS Growth | 19.5% | 3/6 |
| Total Current Assets | $3.97B | 21.0% of assets |
| Cash & Short-term Investments | $262M | 1.4% of assets |
| Accounts Receivable | $2.41B | 12.8% of assets |
| Inventory | $538M | 2.8% of assets |
| Total Liabilities | $10.06B | 53.2% of assets |
| Short-term Debt | $2.08B | 11.0% of assets |
Companies classified under the same SEC industry code as Labcorp Holdings Inc. (Services-Medical Laboratories): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LH Labcorp Holdings Inc. | $28.74B | |
| NTRA Natera, Inc. | $54.62B | |
| DGX Quest Diagnostics Inc | $27.18B | |
| GH Guardant Health, Inc. | $23.48B | |
| CAI Caris Life Sciences, Inc. | $9.70B | |
| GRAL Grail, Inc. | $6.23B | |
| RDNT Radnet, Inc. | $5.78B | |
| BLLN Billiontoone, Inc. | $5.21B | |
| CDNA Caredx, Inc. | $4.52B | |
| VCYT Veracyte, Inc. | $3.94B | |
| CELC Celcuity Inc. | $3.38B | |
| FTRE Fortrea Holdings Inc. | $2.02B | |
| PSNL Personalis, Inc. | $1.68B | |
| FRNM Freenome, Inc. | $1.23B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.08B | |
| CSTL Castle Biosciences Inc | $1.07B | |
| FLGT Fulgent Genetics, Inc. | $533M | |
| BDSX Biodesix Inc | $222M | |
| XGN Exagen Inc. | $203M | |
| BNR Burning Rock Biotech Ltd | $117M | |
| SERA Sera Prognostics, Inc. | $78M | |
| MDXH Mdxhealth Sa | $18M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $5M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| RNLXY Renalytix Plc | N/A |
UBS Adjusts Price Target on Labcorp to $420 From $380, Maintains Buy Rating MT Oct. 29 Morgan Stanley Adjusts Price Target on Labcorp Holdings to $388 From $338 MT Oct. 29 Deutsche Bank Adjusts ...
Headquartered in Burlington, North Carolina, Labcorp Holdings Inc. (LH) operates one of the world’s largest laboratory networks, providing everything from routine diagnostics to oncology, genetics, ...
The average one-year price target for Labcorp Holdings (XTRA:N6B) has been revised to 344,85 € per share. This represents an ...
Our AI scores Labcorp Holdings Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For LH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 21.0%, measured on 358 forecast dates between 2022-08-17 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 1.0%, measured on 400 forecast dates between 2022-08-17 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Labcorp Holdings Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 4, 2026.
27 issuers in our coverage, LH included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
